FIGURE 1.
Screening of nanobodies against the hepatitis E virus (HEV) sp239 protein. (A) Alignment of the amino acid sequences of eight isolated nanobodies. The numbering of frameworks and complementarity-determining regions (CDRs) is based on previous methods (Kabat et al., 1991). (B) The specific binding between sp239 and nanobodies with indirect ELISA. The PCV2-cap protein was used as a control. (C) Titration of the nanobodies. Data were processed with triplicate experiments and are presented as the means ± SDs.
